☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search category
Search here
Search here
Subscribe Now
Prestige BioPharma
Prestige Biopharma Withdraws the MAA for HD201 (biosimilar, trastuzumab) from the EMA
September 16, 2022
Prestige Biopharma Entered into a Binding Agreement with Intas to Commercialize HD204 (biosimilar, bevacizumab) in Multiple Countr...
July 26, 2022
Prestige BioPharma Published Results of HD201 (biosimilar, trastuzumab) for the Treatment of ERBB2+ Breast Cancer in JAMA Oncology
March 24, 2022
Prestige BioPharma Publishes the Results of Tuznue (biosimilar, trastuzumab) in the JAMA Oncology
March 17, 2022
Prestige BioPharma’s Tuznue, a proposed biosimilar to Herceptin Receives EU-GMP Certification for the Treatment of Gastric & Breas...
February 21, 2022
PharmaShots' Key Highlights of Second Quarter 2021
July 7, 2021
Load more...
Back to Home